

Window of opportunity treatment in breast cancer

Julia Chen ¹,* Neshanth Easwaralingam ²,* Sanjay Warriar,³ Andrew Ong,⁴ Emma-Kate Carson,⁵ Cindy Mak,⁶ Kylie Snook,⁷ Kate Middleton,⁸ Andrew Parker,⁹ Carlo Palmieri,¹⁰ Andrew Spillane,¹¹ G. Bruce Mann,¹² Elgene Lim* and Davendra Segara*

*Garvan Institute of Medical Research and St Vincent's Hospital, The University of New South Wales, Sydney, New South Wales, Australia

[†]Chris O'Brien Lifecare and The University of Sydney, Sydney, New South Wales, Australia

[‡]Royal Prince Alfred Hospital Institute of Academic Surgery, The University of Sydney, Sydney, New South Wales, Australia

[§]Campbelltown Hospital and The University of Western Sydney, Sydney, New South Wales, Australia

[¶]Breast and Surgical Oncology at the Poche Centre and Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia

^{||}University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, Liverpool, UK

^{**}Mater Hospital, Sydney, New South Wales, Australia

^{††}Royal North Shore Hospital, Sydney, New South Wales, Australia

^{‡‡}The Royal Melbourne Hospital and The Royal Women's Hospital, Melbourne, Victoria, Australia and

^{§§}Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia

Key words

breast cancer, endocrine therapy, window of opportunity therapy.

Correspondence

Associate Professor Elgene Lim, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, NSW 2010, Australia.
Email: e.lim@garvan.org.au

J. Chen BSc (Med) (Hons), MBBS;

N. Easwaralingam MBBS (Hons), FRACS;

S. Warriar MBBS, FRACS; **A. Ong** MBChB,

FRACS; **E.-K. Carson** MBChB, FRACP; **C. Mak**

MBBS, FRACS; **K. Snook** BMed (Hons), FRACS;

K. Middleton BMedSc, MBBS; **A. Parker** MBBS

(Hons), FRCPA; **C. Palmieri** MRCP, PhD;

A. Spillane MD, FRACS; **G. B. Mann** FRACS,

PhD; **E. Lim** FRACP, PhD; **D. Segara** FRACS,

PhD.

Julia Chen, Neshanth Easwaralingam, Elgene Lim and Davendra Segara contributed equally to this work.

Accepted for publication 12 September 2019.

doi: 10.1111/ans.15487

Introduction

Window of opportunity therapies (WOTs) involve a short period of preoperative systemic therapy between diagnosis and primary surgery. While this approach is not uncommon in the clinical setting, particularly for ensuring there is no progression when there are

Abstract

Window of opportunity therapies, which involve short-term administration of systemic therapy between cancer diagnosis and surgery, have raised significant interest in recent years as a mean of assessing the sensitivity of a patient's cancer to therapy prior to surgery. There is now compelling evidence that in patients with early stage hormone-receptor positive breast cancer, a 2-week preoperative treatment with standard hormone therapies in a preoperative window period provides important prognostic information, which in turn helps to aid decision-making regarding treatment options. Changes in short-term biomarker endpoints such as cell proliferation measured by Ki-67 can act as surrogate markers of long-term outcomes. Paired tissues obtained pre- and post-investigational treatment, without having to subject the patient to additional biopsies, can then be used to conduct translational research to investigate predictive biomarkers and pharmacodynamics. In this review, we will examine the utility and challenges of window of opportunities therapies in breast cancer in the current literature, and the current Australian and international trial landscape in this clinical space.

delays to primary surgery, it is increasingly being employed in a more standardized fashion in a broader population, with a functional readout of biomarkers indicative of treatment response. Unlike standard preoperative systemic therapy approaches, the goal of WOT is to identify a change in a specific biomarker rather than to downstage the cancer. It easily fits into the window patients often

have to wait for primary breast surgery, therefore having little or no impact on the time to surgery. This approach is most validated in the setting of early stage hormone-receptor positive (HR+) breast cancer using Ki-67 as a biomarker, following 2 weeks of preoperative endocrine therapy (ET).

WOT is also frequently utilized in clinical trials setting as a relatively cost and time-efficient tool to functionally assess the response of cancer to new therapies. It provides an opportunity for the rapid assessment of new compounds to provide initial pharmacodynamic parameters.¹ The availability of pre- and post-treatment tissue allows the exploration of biological mechanisms of the drug's activity. In most instances, the definitive treatment is surgery, meaning a substantial amount of post-treatment tissue is available for extensive testing for mechanisms of drug response, drug resistance and predictive biomarkers. This overcomes one of the major barriers of new cancer therapy development, where pre-clinical models are limited by the scarcity of *in vivo* and *in vitro* models that accurately mimic tumour biology in humans.² In this review, we will examine the utility and challenges of WOTs in breast cancer, and clinical trials in this setting.

Systemic therapy in HR+ breast cancer

ET remains the bedrock of systemic adjuvant therapy in HR+ breast cancers. However, there is a large degree of heterogeneity of biological behaviour within these cancers and their response to ET.³ Luminal breast cancers are typically characterized by a long natural history and an ongoing risk of recurrence even after completion of systemic adjuvant therapy.⁴ Therefore 5 years of adjuvant ET is not optimal for all patients with HR+ breast cancer. A major adjunct to adjuvant ET has been the addition of chemotherapy in patients with higher risk of recurrence.⁵ Another approach to these patients is by intensifying adjuvant ET, either through extended adjuvant ET duration, or by combining ovarian suppression with ET in premenopausal women.^{6–8} These approaches however come at a cost of increased morbidity from toxicities of treatment and long-term consequences such as osteoporosis and cardiovascular disease. The key to these approaches is to identify the subset of patients who may benefit most as the absolute benefits are small overall and negligible in patients with low-risk disease.

Window of opportunity ET in breast cancer

A major difference between WOTs and above approaches is that WOTs functionally assess a tumour's response to therapy, while the other approaches are solely based on tumour characteristics, independent of response to therapy. A summary of WOT trials of ET in breast cancer is listed in Table 1a.

Tamoxifen was the first endocrine agent to be evaluated in a WOT trial which randomized 103 breast cancer patients to tamoxifen or placebo in the preoperative window period with a median treatment duration of 3 weeks. A significant decrease in Ki-67 was seen in the tamoxifen-treated patients but not in the placebo group.⁹ Post-WOT Ki-67 predicted both recurrence-free and overall survival.¹⁰ In other studies, different doses and formulations of tamoxifen were evaluated, demonstrating similar effects on Ki-67

expression.^{11,12} The expression of other breast cancer-related biomarkers including insulin-like growth factor-1 and sex hormone binding globulin demonstrated a linear dose–response relationship with tamoxifen in these studies.

Aromatase inhibitors (AIs) are the most extensively studied ET in the window setting. The IMPACT trial randomized 330 patients to receive neoadjuvant tamoxifen, anastrozole or a combination of the two for 12 weeks. This trial was designed to match the ATAC trial, which compared same treatment arms in the adjuvant setting and showed improvement in recurrence-free survival in the anastrozole arm.¹³ Although IMPACT was not strictly a WOT study, biopsies were taken at 2 weeks post-treatment and biological changes in proliferation were assessed by Ki-67 staining, yielding data at a time point consistent with most WOT studies.¹⁴ A reduction in Ki-67 was significantly more pronounced in the anastrozole group compared to the tamoxifen group (76% versus 59.5%), mirroring results of the ATAC trial. Further analyses suggested that higher Ki-67 expression after 2 weeks of therapy was associated with worse recurrence-free survival.¹⁵

Subsequent WOT studies with AIs have explored genome-wide expression profile in attempts to understand the underlying tumour biology and effects of these drugs on a molecular level. In one study, whole exome sequencing of tumours following 10–21 days of WOT with an AI revealed a correlation between genomic aberrations such as *FGFR1* and *CCND1* amplification, and poor response to AI as indicated by high Ki-67 post-treatment.¹⁶ RNA sequencing revealed the presence of intrachromosomal *ESR1* fusion transcripts and increased expression of gene signatures indicative of enhanced E2F-mediated transcription and cell cycle processes in cancers with high Ki-67.¹⁶ Another study observed a similar increased proportion of *FGFR1* amplification in tumours that did not have a Ki-67 response following WOT with letrozole compared with responding tumours. The translational relevance of this finding is supported by preclinical studies that showed FGFR antagonists as effective therapy in endocrine-resistant, *FGFR1*-amplified models.¹⁷ These data suggest that WOT followed by genomic profiling not only provides insights into mechanisms of intrinsic endocrine resistance, it may also be used to identify potentially targetable alterations to overcome this resistance.

The largest WOT study in breast cancer to date is the phase 3 POETIC trial.¹⁸ A total of 4486 postmenopausal women with early-stage HR+ breast cancer were randomized in 2:1 ratio to receive an AI or placebo for 2 weeks prior to and after surgery. Patients then received standard adjuvant therapy. Preliminary analysis after a median follow-up of 60.7 months found that 9.1% of patients had a recurrence of their breast cancer. There was no evidence of an improved time-to-recurrence in the treatment group compared to control group (8.8% versus 9.6%). However, Ki-67 at baseline and at 2 weeks following WOT provided significant and independent prognostic information. Patients with a low Ki-67 (<10%) had a good prognosis and had little additional prognostic data to gain from WOT AI. In contrast, patients whose baseline Ki-67 was high (≥10%) could be stratified into risk groups based on their response to 2 weeks of WOT. The 5-year absolute risk of recurrence was significantly higher in patients with a Ki-67 ≥10% before and after treatment compared with those whose Ki-67 had

Table 1 Window of opportunity trials in breast cancer

Investigators	Design	Participants (n)	Intervention	Control	Duration of therapy (days)	Primary endpoints	Outcome
1a: Endocrine therapy (completed trials) Clarke <i>et al.</i> ⁹	RCT	103	Tamoxifen	Placebo	Median 21	Ki-67 response	Median Ki-67 5.6% to 3% in tamoxifen group, 5.4% to 5.75% in placebo group
Curigliano <i>et al.</i> ²⁰	RCT	14	Ribociclib 400 mg/day or 600 mg/day + letrozole	Letrozole	14	Ki-67 response	Mean Ki-67 decrease from baseline: 69% in letrozole alone, 96% in ribociclib 400 mg/day, 92% in ribociclib 600 mg/day
DeCensi <i>et al.</i> ¹¹	RCT	120	Tamoxifen 1 mg/day or 5 mg/day or 20 mg/day	Untreated control	28	Ki-67 response	Reduction in Ki-67 across all tamoxifen groups. No difference between different tamoxifen doses
DeFriend <i>et al.</i> ⁴⁰	RCT	56	Fulvestrant 6 mg or 18 mg IM daily	No treatment	7	Pharmacodynamics Ki-67 response	Reduction of ER/PgR and Ki-67
Dowsett <i>et al.</i> ⁴¹	RCT	143	Raloxifene 60 mg/day Raloxifene 600 mg/day	Placebo	14	Ki-67 response	21% reduction in Ki-67 in raloxifene 60 mg/day cohort and 14% in 600 mg/day cohort
Ghazoui <i>et al.</i> ⁴²	Single arm	81	Anastrozole 1 mg/day	None	14	Gene expression	Hypoxia metagene significantly downregulated in anastrozole cohort and associated with change in Ki-67
Mackay <i>et al.</i> ⁴³	RCT	34	Letrozole	Anastrozole	14	Gene expression	Changes in oestrogen-dependent genes and proliferation-related genes in both groups
Morrogh <i>et al.</i> ⁴⁴	RCT	26	Anastrozole	No treatment	10	Gene expression, Ki-67 response	Dysregulated oestrogen-related genes and reduction in Ki-67 observed in 54% of patients in treatment group
Robertson <i>et al.</i> ⁴⁵	RCT	201	Fulvestrant 50 mg or 125 mg or 250 mg or tamoxifen	Placebo	14–21	ER/PR, Ki-67 response	Significant reduction in ER expressions across all fulvestrant doses, reduction in PR expression in 125 mg and 250 mg, increase in PR expression in tamoxifen groups. All treatments groups reduced Ki-67
Robertson <i>et al.</i> ¹⁸	RCT	4480	Anastrozole or letrozole	No treatment	14 prior to surgery +14 after surgery 14–21	Time to recurrence Ki-67 response	No difference in TTR, Ki-67 result not reported
Rouanet <i>et al.</i> ¹²	RCT	55	Transdermal tamoxifen 0.5 mg or 1 mg or 2 mg/day or tamoxifen (PO)	No treatment	14–21	Ki-67 response	All treatment groups had reduction in median Ki-67 scores, no difference between 1 mg, 2 mg and oral tamoxifen groups, smaller change in 0.5 mg group
Schmid <i>et al.</i> ⁴⁶	RCT	75	Anastrozole + Pictilisib	Anastrozole	14	Ki-67 response	Greater Ki-67 suppression of 83.3% in combination group compared to 66% in anastrozole group

Table 1 Continued

Investigators	Design	Participants (n)	Intervention	Control	Duration of therapy (days)	Primary endpoints	Outcome
Serrano <i>et al.</i> ⁴⁷	RCT	125	Tamoxifen 10 mg/week or raloxifene 60 mg/day	Placebo	42	Ki-67 response	No change in Ki-67 in either treatment groups
Smith <i>et al.</i> ¹⁴	RCT	330	Tamoxifen + anastrozole	Tamoxifen + placebo or anastrozole + placebo	90 (assessment at 14 and 84 days)	Objective response, Ki-67 response	No difference in OR across the 3 groups Greater reduction in Ki-67 in anastrozole group (mean 76%) at 2 weeks compared to tamoxifen (mean 59.5%), 63.9% in combination group
1b: Endocrine therapy (ongoing trials)							
WINPRO (NCT03906669)	RCT	200	Prometrium + tamoxifen or prometrium + letrozole	Letrozole	14	Ki-67 response	
PIONEER (NCT03306472)	RCT	189	Megestrol 40 mg + letrozole or megestrol 160 mg + letrozole	Letrozole	15	Ki-67 response	
PEARL (ISRCTN23662758)	RCT	112	Tamoxifen + Utrogestan	Tamoxifen	14–18	Ki-67 response	
GDC-9545 (NCT03916744)	Open-label	45	GDC-9545 at 3 dose levels	N/A	14	Ki-67 response	
Emerald (ISRCTN12213700)	RCT	146	Enobosarm	No treatment	14	Ki-67 response	
ARB (NCT02676986)	RCT	221	Enzalutamide + exemestane	Exemestane	14–28	Ki-67 response	

reduced from $\geq 10\%$ to $< 10\%$ following WOT (19.6% versus 8.9%).¹⁸ The hazard ratio for patients with high Ki-67 at both time points was 2.22 ($P < 0.001$). This study supports the routine use of WOT outside clinical trials as a prognostication tool. There are however no current guidelines to use Ki-67 response information to guide subsequent adjuvant therapy.

There are a number of ongoing trials evaluating various endocrine-based therapies in HR+ breast cancer (Table 1b). The WinPro study is one such investigator-initiated study funded by Cancer Council of NSW and Centre for Translational Breast Cancer Research currently recruiting across Australia. This study evaluates 2 weeks of ET alone or in combination with prometrium (micro-ionized progesterone) in postmenopausal patients with newly diagnosed early-stage ER/PR-positive, HER2-negative breast cancer (ClinicalTrials.gov identifier NCT03906669). The rationale for this study is based on seminal preclinical research that has shown additive anti-tumour effect of progesterone in combination with ET in explant and xenograft models.¹⁹ A total of 200 patients will be recruited, randomized to receive letrozole, letrozole plus prometrium or tamoxifen plus prometrium between diagnosis and definitive surgery. The primary endpoint is to determine geometric mean suppression of centrally assessed Ki-67 after 2 weeks of intervention, compared with baseline. Translational endpoints including evaluating a gene set as a predictive biomarker for a reduction in Ki-67 and changes in markers such as Bcl-2, caspase 3, hormone receptors and mRNA expression in tumours following intervention. Functional profiling of endocrine-resistant tumours will hopefully provide more insights into pathways of primary endocrine resistance and potential new therapeutic targets to overcome these. Two similar WOT trials (PIONEER trial, ClinicalTrials.gov identifier NCT03306472; PEARL trial, ISRCTN23662758) are running in parallel in the UK with a plan for combined analysis at the completion of these three trials. Another WOT trial currently accruing in Australia is GDC-9545 (an oral oestrogen receptor degrader, ClinicalTrials.gov identifier NCT03916744), which aims to evaluate the pharmacodynamics and pharmacokinetics at three different doses in parallel with a phase 1 study conducted in the advanced/metastatic setting.

WOT trials in breast cancer with non-ET

In addition to ET, a number of non-endocrine therapies have been tested in the WOT setting, typically but not always in combination with an ET backbone, and with standard ET as a control arm. CDK4/6 inhibitors such as ribociclib and palbociclib have been evaluated in combination with AI in WOT setting to assess anti-proliferative response as well as pharmacokinetics, genetic profiling and safety.^{20,21} Results showed significant reduction in Ki-67 expression with absence of drug–drug interaction between these drugs and AI. Further studies have now established the use of these combinations as standard first line treatments for metastatic HR+ breast cancers.^{22,23} The antiproliferative effects of metformin have been studied in multiple WOT trials and demonstrated a trend toward a decrease in Ki-67 and apoptosis.^{24–26} Statins were also assessed in the WOT setting and was found to reduce proliferation only in tumours that express HMG-CoA reductase, via inhibition of

MAPK pathway.²⁷ While these results have not yet translated into clinically meaningful treatments, they provide valuable insights into their mechanisms of action *in vivo*.

Molecular targeted therapies tested in the WOT setting include epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib, vascular endothelial growth factor antibody bevacizumab and EGFR/HER2 tyrosine kinase inhibitor lapatinib. These trials did not only assess antiproliferative effects of these drugs against ET as standard treatment, but also incorporate exploratory endpoints such as drug-induced molecular changes²⁸ and interaction between different gene signatures,²⁹ which enables identification of potential predictive biomarkers. These studies demonstrate the feasibility of WOTs with targeted agents to guide development of new therapeutic options.

Tissue and short-term biomarker analysis in WOT

Ki-67 is the most commonly used biomarker in endocrine-based WOT in breast cancer. A change in Ki-67 is a validated endpoint linked to treatment efficacy and prognosis.^{15,30} Major limitations of Ki-67 however include variability due to tumour heterogeneity, duration of tissue ischaemia, duration of fixation, immunohistochemical technique used and inter-observer variation.³¹ To overcome some of these limitations, the International Ki-67 in Breast Cancer Working Group has published recommended guidelines for the assessment, interpretation and scoring of Ki-67.³² Adherence to such standardized protocols would help to improve between-laboratory and between-study comparability of this biomarker. In clinical trials setting, central processing of specimens in the same laboratory using standardized protocols and ideally scoring by the same pathologist would also help to mitigate some of these shortfalls.

Evidence for the utility of Ki-67 as a marker of treatment response in other cancers is less well validated, hence the optimal biomarker endpoint for WOTs outside of breast cancer context remains unknown. Other molecular endpoints, such as changes in cell cycle regulators or phosphorylation of targeted growth factors have been utilized both in breast cancer^{28,33} and other types of cancers.^{34,35} These represent potentially feasible endpoints for future window studies but would require standardization and validation to establish their routine use.

With increased utility of more complex techniques such as RNA-based analyses in molecular studies, there is also increased reliance on the quality of preserved tissue. Formalin-fixing and paraffin embedding is the standard form of preservation for biopsy specimens. However, nucleic acids extracted from formalin-fixed paraffin-embedded tissues are often fragmented and chemically modified, making it challenging for isolation of high-quality RNA for genetic profiling.³⁶ Fresh frozen tissues are ideal in overcoming this challenge but require an additional pre-treatment research biopsy. However, for the measurement of immunohistochemistry-based biomarkers such as Ki-67, a dedicated research biopsy is not required, as it can be performed on the diagnostic core biopsy.

Optimal WOT trial design

The ideal trial design for a WOT should involve treatment with the investigational agent for a short period of time, with no delay in curative treatment. The acceptable interval between diagnosis and definitive treatment is not well-defined in the literature, but treatment within 4 weeks of diagnosis is usually considered acceptable.³⁷ The treatment duration should also consider the pharmacokinetics of the drug, such that there is sufficient time to reach steady state. This poses a limitation for drugs with a prolonged half-life. Owing to the time constraint of such studies, screening and consent should ideally be completed at the time of diagnosis. This allows investigators to combine standard investigations with those required by the trial, avoiding the need for repeat biopsies or imaging. The primary endpoint should ideally be a parameter that has been validated as a surrogate marker of treatment activity that affects survival outcomes.³⁸ Another important aspect is evaluation of drug safety and toxicity. Given that these studies are generally conducted in patients prior to their curative surgery, the toxicity profile should be well-studied prior to initiation of treatment to minimize side effects with resultant delays in their definitive treatment. Drugs that may complicate surgery, such as by potentially affecting wound healing, blood cell counts or function are not ideal in this setting.

Study recruitment can be hindered by the need for an additional pre-treatment research biopsy and in some cases serial preoperative imaging, which may dis-incentivize patients. One study found that only 26.7% of patients with newly diagnosed operable breast cancer were agreeable to participate in WOT trials.³⁹ Hence trials with limited additional investigation and biopsies which can be incorporated into a patient's routine work flow prior to surgery will likely have a higher participation rate. Finally, and most importantly, precise co-ordination and good communication within the multi-disciplinary team is mandatory. A lack of awareness from any member of the multi-disciplinary team can impact protocol compliance, timely processing of samples and administration of treatment.

Future directions

The current common practice for early HR+ breast cancers involves proceeding directly to surgery followed by adjuvant treatments, and in a minority of cases, having neoadjuvant systemic therapy to downstage the breast cancer. In Australia, it is not uncommon for there to be a 2- to 4-week window between diagnosis and surgery. With the emerging prognostic value of endocrine WOTs, this window represents an opportunity to incorporate endocrine-based WOT into standard practice for patients (Fig. 1), especially those with a high baseline Ki-67. This is at a minimal cost to patients given well-known safety profile of tamoxifen and AIs, no need for additional investigations and does not impact on the timeliness of their surgical treatment. It will however, provide valuable information regarding the functional response of their tumours, which can then be used as an independent prognostic predictor when considering adjuvant treatment recommendations. Additionally, this strategy will enable the opportunity for biobanking valuable paired pre- and post-treatment tissue for translational research. A major clinical challenge that needs to be addressed is the best strategy to manage




Fig. 1. Management options for early hormone-receptor positive (HR+) breast cancers.

patients who do not obtain a Ki-67 treatment response to WOT, an area where there is little data. At present, one could consider performing a multi-gene assay to weigh up the addition of chemotherapy to ET, or extended ET.

In the context of drug development, there is an increasing number of WOT trials being conducted in Australia and internationally. This represents a cost-effective strategy to generate short-term functional data and biological information on molecular pathways altered by treatment, which will provide opportunities to discover relevant predictive biomarkers for patient selection in subsequent studies, significantly reducing the cost of trialling drugs in a larger, undefined patient population. The identification of altered molecular mechanisms may also be hypothesis-generating whereby evidence of response to treatment via a particular pathway may provide the rationale to test the same agent in a different disease modulated by a similar pathway. Future development may see the use of WOTs as a key modality in the new era of targeted therapies and emerging field of precision medicine using pan-omic analyses.

Conflicts of interest

None declared.

References

1. Marous M, Bieche I, Paoletti X *et al.* Designs of preoperative biomarkers trials in oncology: a systematic review of the literature. *Ann. Oncol.* 2015; **26**: 2419–28.
2. Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. *Curr. Opin. Pharmacol.* 2010; **10**: 375–9.
3. Sorlie T, Perou CM, Tibshirani R *et al.* Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl. Acad. Sci. U. S. A.* 2001; **98**: 10869–74.
4. Pan H, Gray R, Braybrooke J *et al.* 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *N. Engl. J. Med.* 2017; **377**: 1836–46.
5. Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet* 2012; **379**: 432–44.
6. Davies C, Pan H, Godwin J *et al.* Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS a randomised trial. *Lancet* 2013; **381**: 805–16.
7. Goss PE, Ingle JN, Pritchard KI *et al.* Extending aromatase-inhibitor adjuvant therapy to 10 years. *N. Engl. J. Med.* 2016; **375**: 209–19.
8. Francis PA, Pagani O, Fleming GF *et al.* Tailoring adjuvant endocrine therapy for premenopausal breast cancer. *N. Engl. J. Med.* 2018; **379**: 122–37.
9. Clarke RB, Laidlaw IJ, Jones LJ *et al.* Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. *Br. J. Cancer* 1993; **67**: 606–11.
10. DeCensi A, Puntoni M, Pruneri G *et al.* Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. *Cancer Prev. Res.* 2011; **4**: 1181–9.
11. Decensi A, Robertson C, Viale G *et al.* A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. *J Natl Cancer I.* 2003; **95**: 779–90.
12. Rouanet P, Linares-Cruz G, Dravet F *et al.* Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. *J. Clin. Oncol.* 2005; **23**: 2980–7.
13. Baum M, Budzar AU, Cuzick J *et al.* Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002; **359**: 2131–9.
14. Smith IE, Dowsett M, Ebbs SR *et al.* Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative Anastrozole, Tamoxifen, or

- combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. *J. Clin. Oncol.* 2005; **23**: 5108–16.
15. Dowsett M, Smith IE, Ebbs SR *et al.* Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. *J. Natl. Cancer Inst.* 2007; **99**: 167–70.
 16. Giltane JM, Hutchinson KE, Stricker TP *et al.* Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. *Sci. Transl. Med.* 2017; **9**: eaai7993.
 17. Formisano L, Stauffer KM, Young CD *et al.* Association of FGFR1 with ERalpha maintains ligand-independent ER transcription and mediates resistance to Estrogen deprivation in ER(+) breast cancer. *Clin. Cancer Res.* 2017; **23**: 6138–50.
 18. Robertson JFR, Dowsett M, Bliss JM *et al.* Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer - the POETIC* trial (CRUK/07/015). *Cancer Res.* 2018; **78** (4 suppl): S1–S3.
 19. Mohammed H, Russell IA, Stark R *et al.* Progesterone receptor modulates ERalpha action in breast cancer. *Nature* 2015; **523**: 313–7.
 20. Curigliano G, Pardo PG, Meric-Bernstam F *et al.* Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. *Breast* 2016; **28**: 191–8.
 21. Arnedos M, Bayar MA, Cheaib B *et al.* Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. *Ann. Oncol.* 2018; **29**: 1755–62.
 22. Hortobagyi GN, Stemmer SM, Burris HA *et al.* Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N. Engl. J. Med.* 2016; **375**: 1738–48.
 23. Finn RS, Martin M, Rugo HS *et al.* Palbociclib and Letrozole in advanced breast cancer. *N. Engl. J. Med.* 2016; **375**: 1925–36.
 24. Bonanni B, Puntoni M, Cazzaniga M *et al.* Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. *J. Clin. Oncol.* 2012; **30**: 2593–600.
 25. Cazzaniga M, DeCensi A, Pruneri G *et al.* The effect of metformin on apoptosis in a breast cancer presurgical trial. *Br. J. Cancer* 2013; **109**: 2792–7.
 26. Hadad SM, Coates P, Jordan LB *et al.* Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. *Breast Cancer Res. Treat.* 2015; **150**: 149–55.
 27. Bjarnadottir O, Romero Q, Bendahl PO *et al.* Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. *Breast Cancer Res. Treat.* 2013; **138**: 499–508.
 28. Wedam SB, Low JA, Yang SX *et al.* Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. *J. Clin. Oncol.* 2006; **24**: 769–77.
 29. Mehta S, Hughes NP, Buffa FM *et al.* Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. *J. Natl. Cancer Inst. Monogr.* 2011; **2011**: 71–4.
 30. Dowsett M. Optimizing the implementation of future treatment using surrogate end-points. *Breast Cancer Res.* 2008; **10** Suppl 4: S26.
 31. Arnaout A, Robertson S, Kuchuk I *et al.* Evaluating the feasibility of performing window of opportunity trials in breast cancer. *Int. J. Surg. Oncol.* 2015; **2015**: 785793.
 32. Dowsett M, Nielsen TO, A'Hern R *et al.* Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. *J. Natl. Cancer Inst.* 2011; **103**: 1656–64.
 33. Feldt M, Bjarnadottir O, Kimbung S *et al.* Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. *J. Transl. Med.* 2015; **13**: 133.
 34. Ma T, Galimberti F, Erkmen CP *et al.* Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. *Mol. Cancer Ther.* 2013; **12**: 1545–55.
 35. Thomas F, Rochaix P, Benlyazid A *et al.* Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. *Clin. Cancer Res.* 2007; **13**: 7086–92.
 36. Hedegaard J, Thorsen K, Lund MK *et al.* Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. *PLoS One* 2014; **9**: e98187.
 37. Glimelius B, Lahn M. Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. *Ann. Oncol.* 2011; **22**: 1717–25.
 38. Schmitz S, Duhoux F, Machiels JP. Window of opportunity studies: do they fulfil our expectations? *Cancer Treat. Rev.* 2016; **43**: 50–7.
 39. Wisinski KB, Faerber A, Wagner S *et al.* Predictors of willingness to participate in window-of-opportunity breast trials. *Clin. Med. Res.* 2013; **11**: 107–12.
 40. DeFriend DJ, Howell A, Nicholson RI *et al.* Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. *Cancer Res.* 1994; **54**: 408–14.
 41. Dowsett M, Bundred NJ, Decensi A *et al.* Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. *Cancer Epidemiol. Biomarkers Prev.* 2001; **10**: 961–6.
 42. Ghazoui Z, Buffa FM, Dumbier AK *et al.* Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer. *Clin. Cancer Res.* 2011; **17**: 3005–12.
 43. Mackay A, Urruticoechea A, Dixon JM *et al.* Molecular response to aromatase inhibitor treatment in primary breast cancer. *Breast Cancer Res.* 2007; **9**: R37.
 44. Morrogh M, Andrade VP, Patil AJ *et al.* Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole. *J. Surg. Res.* 2012; **176**: 121–32.
 45. Robertson JF, Nicholson RI, Bundred NJ *et al.* Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. *Cancer Res.* 2001; **61**: 6739–46.
 46. Schmid P, Pinder SE, Wheatley D *et al.* Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor Pictilisib plus Anastrozole compared with Anastrozole alone in patients with Estrogen receptor-positive breast cancer. *J. Clin. Oncol.* 2016; **34**: 1987–94.
 47. Serrano D, Lazzaroni M, Gandini S *et al.* A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. *Breast Cancer Res.* 2013; **15**: R47.